Trending...
- Quidax Launches $125,000 Crypto Innovation Pitch, Partners with Moonshot for TC Battlefield - 131
- InventHelp Inventor Develops Convenient Trash Bag Accessory (SBT-1891) - 113
- Celebrating 30 Years: 2024 Diversity Visa Lottery Opens Oct. 2, Offering Life-Changing Opportunities for U.S. Immigration - 107
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming October 2, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) common stock between January 28, 2021 and July 28, 2023, inclusive (the "Class Period").
If you are a shareholder who suffered a loss, click here to participate.
On July 15, 2023, the American Society of Retina Specialists ("ASRS") published a letter regarding its concerns with Apellis's geographic atrophy treatment, SYFOVRE, highlighting physician reports of cases of eye inflammation in patients, including six instances of occlusive retinal vasculitis, which potentially results in blindness. On this news, Apellis's stock price fell $32.04, or 37.9%, to close at $54.46 per share on July 17, 2023, thereby injuring investors.
More on The Californer
On July 17, 2023, after the market closed, Apellis issued a statement addressing the concerns and acknowledging that "[t]he Company is continuing to conduct a thorough investigation of each of the events, working closely with the [ASRS] and several external specialists." On this news, Apellis's stock price fell $12.46, or 23.6%, to close at $40.00 per share on July 18, 2023.
On July 20, 2023, Wedbush downgraded Apellis's price target by more than 50%, from $86.00 per share to $40.00 per share. On this news, Apellis's stock price fell $6.25, or 15.4%, to close at $34.24 per share on July 20, 2023.
Then, on July 29, 2023, Apellis disclosed a seventh occurrence of retinal vasculitis caused by its SYFOVRE treatment, and further stated that it was evaluating a potential eighth reported event of retinal vasculitis. On this news, Apellis's stock price fell $6.27, or 19.6%, to close at $25.75 per share on July 31, 2023, thereby injuring investors further.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the design of SYFOVRE's clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The Californer
Follow us for updates on Twitter: twitter.com/FRC_LAW.
If you purchased or otherwise acquired Apellis common stock during the Class Period, you may move the Court no later than October 2, 2023 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com
If you are a shareholder who suffered a loss, click here to participate.
On July 15, 2023, the American Society of Retina Specialists ("ASRS") published a letter regarding its concerns with Apellis's geographic atrophy treatment, SYFOVRE, highlighting physician reports of cases of eye inflammation in patients, including six instances of occlusive retinal vasculitis, which potentially results in blindness. On this news, Apellis's stock price fell $32.04, or 37.9%, to close at $54.46 per share on July 17, 2023, thereby injuring investors.
More on The Californer
- CRH Healthcare Acquires Four Urgent Care Clinics in Georgia
- Alife's AI Technology Now Available on Hamilton Thorne Laser Systems
- California: An outdated San Francisco DMV will soon become a site for over 370 new homes
- California: Governor Newsom takes action against Norwalk for its unlawful shelter ban
- Major California University to House Author's Original Book Manuscripts on Race and Politics in America
On July 17, 2023, after the market closed, Apellis issued a statement addressing the concerns and acknowledging that "[t]he Company is continuing to conduct a thorough investigation of each of the events, working closely with the [ASRS] and several external specialists." On this news, Apellis's stock price fell $12.46, or 23.6%, to close at $40.00 per share on July 18, 2023.
On July 20, 2023, Wedbush downgraded Apellis's price target by more than 50%, from $86.00 per share to $40.00 per share. On this news, Apellis's stock price fell $6.25, or 15.4%, to close at $34.24 per share on July 20, 2023.
Then, on July 29, 2023, Apellis disclosed a seventh occurrence of retinal vasculitis caused by its SYFOVRE treatment, and further stated that it was evaluating a potential eighth reported event of retinal vasculitis. On this news, Apellis's stock price fell $6.27, or 19.6%, to close at $25.75 per share on July 31, 2023, thereby injuring investors further.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the design of SYFOVRE's clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The Californer
- eCaregivers Launches First-Ever Consumer-Driven Senior Care Platform for Private-Pay Home Care Offering Affordable, Full-Service Agency Experience
- Taiwan Showcases Flavory New Foods During 2024 US and Canada Trade Mission
- SVEA Talent Agency Selects Phillip E Walker for Exclusive Los Angeles Area Commercial Representation
- AKCP - 1 Mega Watt Data Center Facility Under Construction
- Mobility Unicorn inDrive Achieves 1377% ROI & Accelerates Profitability with SHIELD's Device-First Fraud Intelligence USA - English APAC - English
Follow us for updates on Twitter: twitter.com/FRC_LAW.
If you purchased or otherwise acquired Apellis common stock during the Class Period, you may move the Court no later than October 2, 2023 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com
Filed Under: Business
0 Comments
Latest on The Californer
- Zelia do Rosario Teaches Southeast Asia's Hidden Gem to Shine on Voices for Humanity
- Reliance Aerotech Inc. Announces Appointment Of Ron Jordan To Chief Strategy Officer
- California: Governor Newsom statement on the inauguration of President Claudia Sheinbaum
- City of Long Beach Advises Residents to Take Precautions Against Extreme Heat
- One Of A Kind! Lovely & Affordable Home
- California: Assembly advances Governor Newsom's special session proposal to stop gas price spikes
- Upcoming Accordion Concert at The Ebell Theater
- Long Beach Airport Breaks Summer Travel Record
- Stop Fighting, Start Living. Daryl Dittmer's New Book Offers Roadmap to Personal Power
- City of Long Beach Debuts New Water Debris-Collecting Device
- Cygnet Theatre Welcomes Arts Leader James Saba as Major Gifts Officer
- The California Date Commission Announces Sponsorship of the American Diabetes Association's Diabetes Food Hub
- California: Cannabis task force seizes $2.3 million in illegal cannabis and toxic pesticides
- Synthetic Sound Syndicate From TV Records Now Showcased on Spotify With Top Songs
- San Diego Habitat Conservancy Named Finalist in 2024 "Defender Service Awards"
- California gets hundreds of millions of dollars from Biden-Harris Administration for parks, rivers, and clean transportation
- Revolutionizing Mobile Filmmaking: O2 Short Film Shot on iPhone with Beastgrip DOF Adapter Фoton and PL Cinema Lenses
- California: Cal Guard Counterdrug Task Force seizes more than 9.5 million pills with fentanyl
- BTR: Understanding the Critical 2FA Vulnerability in QR Code Enrollment Processes Uncovered by Silent Sector – Lauro Chavez
- Treasury Wine Estates and Hello Sunshine Partner to Introduce New Line of Wines: Drop of Sunshine Female-led Brand Will Further Hello Sunshine's Efforts to Change the Narrative for Women